Completed PHASE2 INTERVENTIONAL 1-arm NCT00683046

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

Sponsor: University of Chicago

Conditions Acute Myelogenous Leukemia Anemia, Aplastic Chronic Lymphocytic Leukemia Chronic Myelogenous Leukemia Hodgkin's Disease Lymphoid Leukemia Malignant Lymphoma Myelodysplastic Syndromes Myeloproliferative Disorder

Interventions Campath Fludarabine Melphalan Stem cells

Updated 7 times since 2017 Last updated: Oct 7, 2016 Started: Nov 30, 2001 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Acute Myelogenous Leukemia and Anemia, Aplastic and is currently completed. University of Chicago leads this study, which shows 7 recorded versions since 2001 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Chicago

Data source: University of Chicago

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States